A major international study, published this week in JAMA Psychiatry, has identified a powerful new brain-based biomarker for ...

Willis Knighton Health in Shreveport, Louisiana, has opened a new nuclear oncology department, the first in the region. The ...

The annual incidence of cardiac sarcoidosis is low, but increased awareness of this inflammatory condition has led to earlier ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

GE HealthCare completes acquisition of leading radiopharmaceutical company, Nihon Medi-Physics in Japan: Chicago Tuesday, April 1, 2025, 12:00 Hrs [IST] GE HealthCare Technologies ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

Curium Pharma has completed its acquisition of Eczacıbaşı-Monrol Nuclear Products Co., enhancing its capacity in nuclear ...

UK MHRA approves trofolastat for diagnostic imaging of prostate cancer in men: United Kingdom Monday, March 31, 2025, 15:00 Hrs [IST] The Medicines and Healthcare products Regulat ...

GE HealthCare Technologies Inc. (GE HealthCare or the Company) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ...